Lataa...
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation
BACKGROUND: Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. In clinical trials, the most common adverse events observed were nasopharyngitis, upper respiratory tract infections, and zoster. JAKs are...
Tallennettuna:
| Julkaisussa: | Arthritis Res Ther |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8138978/ https://ncbi.nlm.nih.gov/pubmed/34020693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-021-02509-8 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|